

Christopher H Hawkes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5044537/publications.pdf>

Version: 2024-02-01

60
papers

4,502
citations

304743
22
h-index

189892
50
g-index

63
all docs

63
docs citations

63
times ranked

5829
citing authors

#	ARTICLE	IF	CITATIONS
1	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	2.0	11
2	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	2.0	10
3	Is multiple sclerosis overdiagnosed?. Multiple Sclerosis and Related Disorders, 2021, 47, 102721.	2.0	2
4	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	2.0	3
5	Melatonin and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 103032.	2.0	2
6	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 53, 103155.	2.0	12
7	Smell, taste and COVID-19: testing is essential. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 83-91.	0.5	7
8	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. Multiple Sclerosis and Related Disorders, 2021, 56, 103426.	2.0	0
9	Is the incidence of multiple sclerosis really increasing?. Multiple Sclerosis and Related Disorders, 2020, 45, 102527.	2.0	4
10	Parosmia: treatment, mechanism, and types. BMJ, The, 2020, 371, m4739.	6.0	11
11	Dare we mention the C-word?. Multiple Sclerosis and Related Disorders, 2020, 43, 102340.	2.0	0
12	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	2.0	8
13	Chemosensory dysfunction in neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 164, 325-360.	1.8	58
14	Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. Multiple Sclerosis and Related Disorders, 2019, 35, A1-A2.	2.0	0
15	Diagnosing and caring for MS in Haiti. Multiple Sclerosis and Related Disorders, 2018, 22, A1-A2.	2.0	0
16	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders, 2018, 25, 197-199.	2.0	14
17	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
18	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90

#	ARTICLE	IF	CITATIONS
19	Risk associated behavior in premorbid multiple sclerosis: A case-control study. Multiple Sclerosis and Related Disorders, 2014, 3, 40-47.	2.0	9
20	Editors' welcome and a working definition for a multiple sclerosis cure. Multiple Sclerosis and Related Disorders, 2013, 2, 65-67.	2.0	59
21	Multiple sclerosis genetics is dead. Multiple Sclerosis and Related Disorders, 2013, 2, 156-161.	2.0	5
22	Comment to letter: "Identical twins with LRRK2 mutation discordant for Parkinson's disease". Movement Disorders, 2013, 28, 561-561.	3.9	2
23	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
24	Identifying prodromal Parkinson's disease: Pre-motor disorders in Parkinson's disease. Movement Disorders, 2012, 27, 617-626.	3.9	443
25	MRI and visual-evoked potentials in partners of multiple sclerosis patients. Acta Neurologica Scandinavica, 2012, 125, 424-430.	2.1	1
26	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. Multiple Sclerosis and Related Disorders, 2012, 1, 9-14.	2.0	37
27	Multiple sclerosis and risk behavior. Multiple Sclerosis and Related Disorders, 2012, 1, 59-60.	2.0	1
28	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathologica, 2010, 119, 703-713.	7.7	258
29	Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?. European Neurology, 2010, 63, 29-35.	1.4	12
30	The McDonald Criteria for Multiple Sclerosis: time for clarification. Multiple Sclerosis Journal, 2010, 16, 566-575.	3.0	43
31	A timeline for Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 79-84.	2.2	470
32	Get rid of your stethoscope!. Practical Neurology, 2010, 10, 344-346.	1.1	3
33	Neurodegenerative diseases that affect olfaction. , 2009, , 153-214.		0
34	Parkinson's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 615-622.	3.8	233
35	Neuropoppycockology. Practical Neurology, 2009, 9, 347-352.	1.1	1
36	Abnormality of taste and smell in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 232-237.	2.2	79

#	ARTICLE	IF	CITATIONS
37	Twin studies and the heritability of MS: a conclusion. Multiple Sclerosis Journal, 2009, 15, 661-667.	3.0	85
38	I've stopped examining patients!. Practical Neurology, 2009, 9, 192-194.	1.1	10
39	Parkinson's disease and aging: Same or different process?. Movement Disorders, 2008, 23, 47-53.	3.9	43
40	The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?. Movement Disorders, 2008, 23, 1799-1807.	3.9	115
41	Olfactory tests in the diagnosis of essential tremor. Parkinsonism and Related Disorders, 2008, 14, 563-568.	2.2	67
42	Smoking is a risk factor for multiple sclerosis: a metanalysis. Multiple Sclerosis Journal, 2007, 13, 610-615.	3.0	121
43	Parkinson's disease: a dual-hit hypothesis. Neuropathology and Applied Neurobiology, 2007, 33, 599-614.	3.2	776
44	Multiple sclerosis in Latter Day Saints (Mormons). Acta Neurologica Scandinavica, 2007, 115, 260-264.	2.1	4
45	Seroprevalence of herpes simplex virus type 2 in multiple sclerosis. Acta Neurologica Scandinavica, 2006, 114, 363-367.	2.1	16
46	Olfaction in Neurodegenerative Disorder. , 2006, 63, 133-151.		116
47	Are multiple sclerosis patients risk-takers?. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 895-911.	0.5	33
48	Why Bother Testing the Sense of Smell?. Practical Neurology, 2005, 5, 224-229.	1.1	3
49	Olfactory testing in parkinsonism. Lancet Neurology, The, 2004, 3, 393-394.	10.2	18
50	Olfaction in neurodegenerative disorder. Movement Disorders, 2003, 18, 364-372.	3.9	265
51	Smart handles and red flags in neurological diagnosis. British Journal of Hospital Medicine, 2002, 63, 732-742.	0.2	5
52	The role of inheritance in sporadic Parkinson's disease. Annals of Neurology, 2000, 47, 682-682.	5.3	1
53	Is Parkinson's disease a primary olfactory disorder?. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 473-480.	0.5	144
54	Olfactory Evoked Responses and Identification Tests in Neurological Disease. Annals of the New York Academy of Sciences, 1998, 855, 608-615.	3.8	85

#	ARTICLE	IF	CITATIONS
55	Twin Study Using Mortality Data: A New Sampling Method. International Journal of Epidemiology, 1995, 24, 758-762.	1.9	2
56	Iso-electric focusing of aqueous humour IgG in multiple sclerosis. Journal of Neurology, 1994, 241, 436-438.	3.6	8
57	Clinical evaluation. , 0, , 59-110.		1
58	Investigation, treatment, and general management of olfactory disease. , 0, , 215-232.		0
59	General disorders of olfaction. , 0, , 111-152.		1
60	Neurodegenerative Chemosensory Disorders. , 0, , 293-386.		0